Trial on the efficacy of propranolol on the progression of varices in patients with cirrhosis

Prospective randomised controlled trial on the efficacy of propranolol on the progression of small varices /no varices in patients with cirrhosis of the liver. Treatment with propranolol versus no treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2007/001

Enrollment

210

Registered

2007-02-23

Start date

2003-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oesophageal varices

Interventions

Treatment with propranolol

Eligibility

Inclusion criteria

Inclusion criteria: Patients with clinical, biochemical, radiological features of cirrhosis confirmed wherever possible by histology 18 -70 years of age Patients with no varices or small varices (less than 5mm) No history of upper GI bleeding Patients not on any vasoactive medications

Exclusion criteria

Exclusion criteria: •Patients who do not fulfill inclusion criteria •Patients currently on primary prophylaxis •Patients with severe obesity •Patients with oesophageal varices more than 5mm •Patients with gastric varices •Patients with contraindications for beta blockers •Patients with hepatocellular carcinoma •Patients with portal vein thrombosis

Design outcomes

Primary

Measure	Time frame
Enlargemert of varices beyond 5mm Bleeding from oesophageal varices [2 years]	—

Secondary

Measure	Time frame
None [None]	—

Countries

Sri Lanka

Contacts

Public ContactDr Anuradha Dassanayake

Senior Lecturer

anuradhadassanayake@hotmail.com+94 112961157

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026